Lack Of Competition Thwarts Roche’s PPMS Bid For Ocrevus At UK’s NICE

Roche’s Ocrevus is having a rough ride through NICE, the UK health technology appraisal body, because there are no other treatments available to slow down the disease, says the company.

Multiple sclerosis
NICE Declines To Recommend Roche's Ocrevus In PPMS • Source: Shutterstock

The UK’s health technology appraisal body, NICE, has rejected Roche’s Ocrevus (ocrelizumab) for primary progressive multiple sclerosis (PPMS) and Steba Biotech’s Tookad (padeliporfin) for prostate cancer because they are not cost-effective options for use on the National Health Service. According to Roche, the job of convincing NICE to recommend Ocrevus’ was more difficult because there are no other disease modifying agents available.

On June 29, NICE, the National Institute for Health and Care Excellence, published preliminary draft guidance declining to recommend Ocrevus...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography